

groups with parents of young children to gather information about their experiences looking for CCEE. The study will collect information about (a) the selected consumer education strategies; (b) implementation successes and challenges; and (c) parents'

experiences looking for CCEE, including the resources they used and their awareness of and perspectives on state/local consumer education resources.

Respondents: State, Territory, and Tribal CCDF program administrators and agency staff, consumer education

services staff, key informants who interact with parents and provide a state/local perspective, and parents/guardians of children under age 6.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Average burden per response (in hours)	Total/annual burden (in hours)
Interview Guide for State, Tribal, and Territory CCDF Administrators	12	1	1	12
Interview Guide for Consumer Education Services Staff	30	1	1	30
Key Informant Interview Guide	18	1	.75	14
Parent Focus Group Facilitator's Guide	120	1	1.5	180
Focus Group Brief Questionnaire	120	1	.1	12

Estimated Total Annual Burden Hours: 248.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: Child Care and Development Block Grant (CCDBG) Act of 1990, as amended (42 U.S.C. 9857 *et seq.*)

Mary B. Jones,
ACF/OPRE Certifying Officer.

[FR Doc. 2022-22759 Filed 10-19-22; 8:45 am]

BILLING CODE 4184-23-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Domestic Victims of Human Trafficking Program Data (OMB #0970-0542)

AGENCY: Office on Trafficking in Persons, Administration for Children and Families, Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Office on Trafficking in Persons (OTIP), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is requesting renewal with revisions of an approved information collection: Domestic Victims of Human Trafficking (DVHT) Program Data (OMB #0970-0542; expiration date 3/31/2023).

DATES: *Comments due within 30 days of publication.* OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function. You can also obtain copies of the proposed collection of information by emailing infocollection@acf.hhs.gov. Identify all emailed requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The Trafficking Victims Protection Act of 2000 (TVPA), as amended, authorizes the HHS Secretary to expand benefits and services to victims of severe forms of trafficking in persons in the United States, without regard to their immigration status. The TVPA also authorizes HHS to establish and strengthen programs to assist United States citizens and lawful

permanent residents who have experienced sex trafficking or severe forms of trafficking in persons (22 U.S.C. 7105(f)(1)). Acting under a delegation of authority from the Secretary of HHS, ACF awards cooperative agreements to organizations to establish a program to assist United States citizens and lawful permanent residents who have experienced human trafficking, the DVHT Program. The DVHT Program is inclusive of two distinct programs: the Domestic Victims of Human Trafficking Services and Outreach Program (DVHT-SO), and the Demonstration Grants to Strengthen the Response to Victims of Human Trafficking in Native Communities Program (VHT-NC). Through the DVHT Program, grant recipients provide comprehensive case management to domestic survivors of human trafficking in traditional case management and Native community settings.

OTIP proposes to continue to collect information to measure grant project performance, provide technical assistance to grant recipients, assess program outcomes, inform program evaluation, respond to congressional inquiries and mandated reports, and inform policy and program development that is responsive to the needs of victims.

The information collection captures information on participant demographics (*e.g.*, age, gender identity, race/ethnicity), type of trafficking experienced (sex, labor, or both), types of services and benefits provided, along with aggregate information on outreach activities conducted, subrecipients enrolled, and the types of trainings provided to relevant audiences. Minor updates have been made to performance indicators under this collection in

consultation with existing grant recipients and stakeholders, to reduce respondent burden and strengthen privacy and confidentiality. Specifically, to reduce burden and strengthen client privacy and confidentiality, the following DVHT client-level indicators have been removed: Type of Intake, Date of Birth, Services Requested at Intake, Benefits Requested at Intake, Trafficker Relationship to Victim, and Employment Status at Case Closure. To

reduce respondent burden, additional outreach and subrecipient indicators have also been removed: Screening Tool Used During Outreach, Goal of Subrecipient Partnership, Type of Subrecipient Partnership; Services Provided by Subrecipient (In-House) and Services Provided by Subrecipient (by Referral) have been collapsed into one category: Services Provided By Subrecipient. A currently approved form under this collection, the DVHT Spending Form, was renamed to

Categories of Assistance and categories of assistance on the Spending Form have been simplified to reduce reporting burden. This form was inadvertently not included on the **Federal Register** Notice inviting initial comments on this collection (87 FR 45107) but has been included for comment here and is included in the request to OMB.

Respondents: DVHT Program Grant Recipients and Clients of those programs, specifically DVHT-SO and VHT-NC funding recipients.

ANNUAL BURDEN ESTIMATES

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total burden hours	Annual burden hours
Client Characteristics and Program Entry	1,700	1	0.75	1,275	425
Client Case Closure	1,700	1	0.167	283.9	94.6
Barriers to Service Delivery and Monitoring	35	4	0.167	23.4	7.8
Client Service Use and Delivery	1,700	1	0.25	425	141.7
Victim Outreach	35	4	0.3	42	14
Training	35	4	0.5	70	23.3
Subrecipient Enrollment	35	3	0.167	17.5	5.8
Categories of Assistance	35	1	.75	26.25	8.75

Estimated Total Annual Burden Hours: 720.95.

Authority: 22 U.S.C. 7105.

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2022–22757 Filed 10–19–22; 8:45 am]

BILLING CODE 4184–47–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0655]

Animal Generic Drug User Fee Act; Public Meeting; Request for Comments; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is extending the comment period for the notice announcing a public meeting and requesting comments that appeared in the **Federal Register** of September 30, 2022. In that notice, FDA announced a public meeting to discuss the proposed recommendations for the reauthorization of the Animal Generic Drug User Fee Act (AGDUFA IV) for fiscal years 2024 through 2028 and that the comment period would be open

until November 9, 2022. FDA is taking this action due to a delay in the posting of the AGDUFA IV Performance Goals and Procedures Letter. This extension will provide the public 30 days to comment as required.

DATES: FDA is extending the comment period announced in the notice of public meeting and request for comments published September 30, 2022 (87 FR 59441). Either electronic or written comments on the notice must be submitted by November 14, 2022, to ensure that the Agency considers your comments regarding this public meeting and request for comments.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of November 14, 2022. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your

comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–